

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US2004/036173

International filing date: 28 October 2004 (28.10.2004)

Document type: Certified copy of priority document

Document details: Country/Office: US
Number: 60/516,323
Filing date: 31 October 2003 (31.10.2003)

Date of receipt at the International Bureau: 25 May 2007 (25.05.2007)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse



THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

May 18, 2007

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

APPLICATION NUMBER: 60/516,323

FILING DATE: *October 31, 2003*

RELATED PCT APPLICATION NUMBER: PCT/US04/36173

THE COUNTRY CODE AND NUMBER OF YOUR PRIORITY APPLICATION, TO BE USED FOR FILING ABROAD UNDER THE PARIS CONVENTION, IS *US60/516,323*



Certified by

Under Secretary of Commerce
for Intellectual Property
and Director of the United States
Patent and Trademark Office

METHODS FOR REDUCING SEIZURE-INDUCED NEURONAL DAMAGE

5 Throughout the application, various publications are
referenced. Full citations for these publications may be
found immediately preceding the claims. The disclosures of
these publications are hereby incorporated by reference
into this application in order to more fully describe the
10 state of the art as of the date of the invention described
and claimed herein.

Background of the Invention

15 *Seizures*

Human seizure disorders are a substantial health problem
because of the large number of affected individuals and the
variety of different syndromes. For example, an estimated
20 1% of the U.S. population is affected by over 40 different
syndromes that make up the epilepsies (1, 2). All
individuals are potentially vulnerable to seizures; they
can occur in anyone following a sufficiently intense insult
to the brain (3). Although seizures can occur in most
25 anyone, individuals vary in what constitutes a seizure-
inducing stimulus (4, 5). Some individuals have high
seizure susceptibility such that they suffer spontaneous
seizures while others have low susceptibility such that
even head trauma or certain brain tumors would not lead to
30 seizures (4).

Receptor for Advanced Glycation Endproducts (RAGE)

Receptor for Advanced Glycation Endproduct (RAGE) is a member of the immunoglobulin superfamily of cell surface molecules first discovered because of its interaction with products of nonenzymatic glycooxidation termed Advanced Glycation Endproducts (AGEs) (6). Subsequently, two endogenous ligands of RAGE have been identified, members of the S100/calgranulin family and the high mobility group I-type polypeptide amphoterin (7, 8). Whereas amphoterin appears to be expressed at high levels in tumors and during development (8-10), S100/calgranulins in the extracellular space are well-known for their association with inflammatory disorders; they have been found in colitis, arthritis, cystic fibrosis, and chronic bronchitis (11). RAGE has been identified as a central signal transduction receptor mediating effects of S100/calgranulins on key cellular targets, including mononuclear phagocytes (MPs), lymphocytes and vascular endothelium (7). The potential physiologic significance of this interaction was emphasized by inhibition of the delayed-type hypersensitivity response by blockade of RAGE-S100/calgranulin interaction (7).

25

30

Summary of the Invention

This invention provides a method for treating a subject either during or soon after a seizure, in order to reduce the extent of neuronal damage in the subject resulting from the seizure comprising administering to the subject, either during or soon after the seizure, a therapeutically effective amount of an inhibitor of receptor for advanced glycation endproducts (RAGE), so as to thereby reduce the extent of neuronal damage in the subject.

This invention further provides a method for inhibiting neuronal damage which would otherwise result from a seizure in a subject predisposed to having a seizure, comprising administering to the subject a prophylactically effective amount of an inhibitor of receptor for advanced glycation endproducts (RAGE), so as to inhibit neuronal damage which would otherwise result from a seizure in the event the subject were to suffer a seizure.

This invention further provides an article of manufacture comprising (a) a packaging material having therein an inhibitor of receptor for advanced glycation endproducts (RAGE) and (b) instructions for using the inhibitor to treat a subject during or soon after a seizure, in order to reduce the extent of neuronal damage in the subject resulting from the seizure.

Finally, this invention provides an article of manufacture comprising (a) a packaging material having therein an inhibitor of receptor for advanced glycation endproducts (RAGE) and (b) instructions for using the inhibitor to

inhibit neuronal damage which would otherwise result from a seizure in a subject predisposed to having a seizure.

5

10

15

20

25

30

Detailed Description of the Invention

Definitions

5 "Administering" an agent can be effected or performed using any of the various methods and delivery systems known to those skilled in the art. The administering can be performed, for example, intravenously, orally, nasally, via the cerebrospinal fluid, via implant, transmucosally,
10 transdermally, intramuscularly, and subcutaneously. The following delivery systems, which employ a number of routinely used pharmaceutically acceptable carriers, are only representative of the many embodiments envisioned for administering compositions according to the instant
15 methods.

Injectable drug delivery systems include solutions, suspensions, gels, microspheres and polymeric injectables, and can comprise excipients such as solubility-altering
20 agents (e.g., ethanol, propylene glycol and sucrose) and polymers (e.g., polycaprylactones and PLGA's). Implantable systems include rods and discs, and can contain excipients such as PLGA and polycaprylactone.

25 Oral delivery systems include tablets and capsules. These can contain excipients such as binders (e.g., hydroxypropylmethylcellulose, polyvinyl pyrrolidone, other cellulosic materials and starch), diluents (e.g., lactose and other sugars, starch, dicalcium phosphate and
30 cellulosic materials), disintegrating agents (e.g., starch polymers and cellulosic materials) and lubricating agents (e.g., stearates and talc).

Transmucosal delivery systems include patches, tablets, suppositories, pessaries, gels and creams, and can contain excipients such as solubilizers and enhancers (e.g.,
5 propylene glycol, bile salts and amino acids), and other vehicles (e.g., polyethylene glycol, fatty acid esters and derivatives, and hydrophilic polymers such as hydroxypropylmethylcellulose and hyaluronic acid).

10 Dermal delivery systems include, for example, aqueous and nonaqueous gels, creams, multiple emulsions, microemulsions, liposomes, ointments, aqueous and nonaqueous solutions, lotions, aerosols, hydrocarbon bases and powders, and can contain excipients such as
15 solubilizers, permeation enhancers (e.g., fatty acids, fatty acid esters, fatty alcohols and amino acids), and hydrophilic polymers (e.g., polycarbophil and polyvinylpyrrolidone). In one embodiment, the pharmaceutically acceptable carrier is a liposome or a
20 transdermal enhancer.

Solutions, suspensions and powders for reconstitutable delivery systems include vehicles such as suspending agents (e.g., gums, zanthans, cellulose and sugars), humectants
25 (e.g., sorbitol), solubilizers (e.g., ethanol, water, PEG and propylene glycol), surfactants (e.g., sodium lauryl sulfate, Spans, Tweens, and cetyl pyridine), preservatives and antioxidants (e.g., parabens, vitamins E and C, and ascorbic acid), anti-caking agents, coating agents, and
30 chelating agents (e.g., EDTA).

"Antibody" shall include, by way of example, both naturally occurring and non-naturally occurring antibodies. Specifically, this term includes polyclonal and monoclonal antibodies, and antigen-binding fragments (e.g., Fab fragments) thereof. Furthermore, this term includes chimeric antibodies (e.g., humanized antibodies) and wholly synthetic antibodies, and antigen-binding fragments thereof.

"Anti-sense nucleic acid" shall mean any nucleic acid which, when introduced into a cell (directly or via expression of another nucleic acid directly introduced into the cell), specifically hybridizes to at least a portion of an mRNA in the cell encoding a protein (i.e., target protein) whose expression is to be inhibited, and thereby inhibits the target protein's expression.

"Catalytic nucleic acid" shall mean a nucleic acid, such as a DNzyme, that specifically recognizes a distinct substrate and catalyzes the chemical modification of this substrate.

"DNzyme" shall mean a catalytic nucleic acid that is DNA or whose catalytic component is DNA, and which specifically recognizes and cleaves a distinct target nucleic acid sequence, which can be either DNA or RNA. Each DNzyme has a catalytic component (also referred to as a "catalytic domain") and a target sequence-binding component consisting of two binding domains, one on either side of the catalytic domain.

"Inhibiting" neuronal damage shall mean either lessening the likelihood of the damage's onset, or preventing damage

entirely. In the preferred embodiment, inhibiting neuronal damage means preventing the damage entirely.

"Nucleic acid" shall mean any nucleic acid molecule, including, without limitation, DNA, RNA and hybrids thereof. The nucleic acid bases that form nucleic acid molecules can be the bases A, C, G, T and U, as well as derivatives thereof. Derivatives of these bases are well known in the art, and are exemplified in PCR Systems, Reagents and Consumables (Perkin Elmer Catalogue 1996-1997, Roche Molecular Systems, Inc., Branchburg, New Jersey, USA).

"Prophylactically effective amount" means an amount sufficient to inhibit the onset of a disorder or a complication associated with a disorder in a subject.

"RAGE" shall mean, without limitation, receptor for advanced glycation endproducts, and can be from human or any other species which produces this protein. The nucleotide and protein (amino acid) sequences for RAGE (both human and murine and bovine) are known. The following references, inter alia, provide these sequences: Schmidt et al, J. Biol. Chem., 267:14987-97, 1992; and Neeper et al, J. Biol. Chem., 267:14998-15004, 1992. Additional RAGE sequences (DNA sequences and translations) are available from GenBank.

"Ribozyme" shall mean a catalytic nucleic acid molecule which is RNA or whose catalytic component is RNA, and which specifically recognizes and cleaves a distinct target nucleic acid sequence, which can be either DNA or RNA. Each ribozyme

has a catalytic component (also referred to as a "catalytic domain") and a target sequence-binding component consisting of two binding domains, one on either side of the catalytic domain.

5

"RNAi" includes, without limitation, a polynucleotide sequence identical or homologous to a target gene (or fragment thereof) linked directly, or indirectly, to a polynucleotide sequence complementary to the sequence of the target gene (or fragment thereof). The RNAi optionally comprises a polynucleotide linker sequence of sufficient length to allow for the two polynucleotide sequences to fold over and hybridize to each other. The linker sequence is designed to separate the antisense and sense strands of RNAi significantly enough to limit the effects of steric hindrances and allow for the formation of a dsRNA molecule, and not to hybridize with sequences within the hybridizing portions of the dsRNA molecule. RNAi is discussed, e.g., in U.S. Patent No. 6,544,783).

20

"Specifically inhibit" the expression of a protein shall mean to inhibit that protein's expression (a) more than the expression of any other protein, or (b) more than the expression of all but 10 or fewer other proteins.

25

"Subject" shall mean any animal, such as a human, non-human primate, mouse, rat, guinea pig or rabbit.

"Therapeutically effective amount" means an amount sufficient to treat a subject afflicted with a disorder or a complication associated with a disorder.

30

Embodiments of the Invention

This invention provides a method for treating a subject either during or soon after a seizure, in order to reduce the extent of neuronal damage in the subject resulting from the seizure comprising administering to the subject, either during or soon after the seizure, a therapeutically effective amount of an inhibitor of receptor for advanced glycation endproducts (RAGE), so as to thereby reduce the extent of neuronal damage in the subject. In the preferred embodiment, the subject is human.

In one embodiment of the instant method, the neuronal damage comprises cell death in the hippocampus and/or cerebral cortex. In another embodiment of the instant method, the neuronal damage comprises cell dysfunction in the hippocampus and/or cerebral cortex.

In one embodiment of the instant method, the inhibitor is an antibody which, when contacted with RAGE, specifically inhibits binding between RAGE and a ligand thereof. In another embodiment of the instant method, the inhibitor is an anti-sense molecule which specifically inhibits the expression of RAGE in a cell. In another embodiment of the instant method, the inhibitor is an RNAi molecule which specifically inhibits the expression of RAGE in a cell. In still another embodiment of the instant method, the inhibitor is a catalytic nucleic acid which specifically inhibits the expression of RAGE in a cell.

30

In further embodiments, the inhibitor is administered during the seizure, within three days of the seizure,

within one day of the seizure, within six hours of the seizure, within one hour of the seizure or within 20 minutes of the seizure.

5 This invention further provides a method for inhibiting neuronal damage which would otherwise result from a seizure in a subject predisposed to having a seizure, comprising administering to the subject a prophylactically effective amount of an inhibitor of receptor for advanced glycation
10 endproducts (RAGE), so as to inhibit neuronal damage which would otherwise result from a seizure in the event the subject were to suffer a seizure. In the preferred embodiment, the subject is human.

15 In one embodiment of the instant method, the neuronal damage comprises cell death in the hippocampus and/or cerebral cortex. In another embodiment of the instant method, the neuronal damage comprises cell dysfunction in the hippocampus and/or cerebral cortex.

20 In one embodiment of the instant method, the inhibitor is an antibody which, when contacted with RAGE, specifically inhibits binding between RAGE and a ligand thereof. In another embodiment of the instant method, the inhibitor is
25 an anti-sense molecule which specifically inhibits the expression of RAGE in a cell. In another embodiment of the instant method, the inhibitor is an RNAi molecule which specifically inhibits the expression of RAGE in a cell. In still another embodiment of the instant method, the
30 inhibitor is a catalytic nucleic acid which specifically inhibits the expression of RAGE in a cell.

This invention further provides an article of manufacture comprising (a) a packaging material having therein an inhibitor of receptor for advanced glycation endproducts (RAGE) and (b) instructions for using the inhibitor to
5 treat a subject during or soon after a seizure, in order to reduce the extent of neuronal damage in the subject resulting from the seizure.

This invention further provides an article of manufacture
10 comprising (a) a packaging material having therein an inhibitor of receptor for advanced glycation endproducts (RAGE) and (b) instructions for using the inhibitor to inhibit neuronal damage which would otherwise result from a seizure in a subject predisposed to having a seizure.

15

This invention is illustrated in the Experimental Details section which follows. This section is set forth to aid in an understanding of the invention but is not intended to, and should not be construed to limit in any way the
20 invention as set forth in the claims which follow thereafter.

25

30

Experimental Details

Introduction

5 RAGE (Receptor for Advanced Glycation Endproducts) is a member of the immunoglobulin superfamily of cell surface molecules with a diverse repertoire of ligands. Based on its capacity to bind AGEs (advanced glycation endproducts), beta-sheet fibrils, S100/calgranulins and amphoterin, RAGE
10 appears to function as a progression factor promoting pathologic cellular activation in a range of situations. It is hypothesized that RAGE activation promotes seizure-induced cell death following experimentally induced status epilepticus.

15

Materials and Methods

Transgenic mice were generated with targeted neuronal overexpression of either wild-type RAGE (Tg wtRAGE) or
20 dominant-negative RAGE, a form lacking the receptor's cytosolic tail (Tg DN-RAGE). Both groups of Tg mice and age- and strain-matched littermate controls were challenged with either systemic kainic acid or pilocarpine. Homozygous RAGE null mice were similarly studied. Acute
25 seizure-induced neuronal damage was examined over the next 1-5 days by silver and FluoroJade staining.

Results

30 Both Tg wtRAGE and Tg DN-RAGE displayed prominent upregulation of RAGE. Overexpression these transgenes did

not affect seizure severity or seizure-induced mortality in response to either pilocarpine or kainic acid administration. However, following status epilepticus induced by either of these agents, seizure-induced neuronal damage was significantly increased in the CA1 and CA3 hippocampal subfields in Tg wtRAGE ($p < 0.05$), compared with littermate controls. In contrast, damage was strongly reduced in Tg DN-RAGE mice ($p < 0.05$). Consistent with these data, RAGE null mice displayed a 70-80% reduction in cell death in CA1 and CA3 regions, compared with littermate controls ($p < 0.05$).

Discussion

Following kainic acid- or pilocarpine-induced status epilepticus, RAGE promotes hippocampal neuronal damage. Blockade of RAGE-ligand interaction provides a novel neuroprotective strategy for the prevention of seizure-induced neurotoxicity.

References

1. Hauser, W. A. and Hesdorffer, D. C. New York: Demos, (1990).
- 5 2. McNamara, J. O. J. Neurosci. 14(6):3413-3425 (1994).
3. Noebels, J. L. Neuron 16(2):241-244 (1996).
- 10 4. Walton, L. Essentials of Neurology. 6th ed Churchill Livingstone Pub, 77-86 (1989).
5. Sackeim, H. A. et al. Arch. Gen. Psych. 44(4):355-360 (1987).
- 15 6. Schmidt, A-M., Yan, S-D., Yan, S-F. & Stern, D.M. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 108, 949-955 (2001)
- 20 7. Hofmann, M., et al. RAGE mediates a novel proinflammatory axis: the cell surface receptor for S100/calgranulin polypeptides. Cell 97, 889-901 (1999).
- 25 8. Taguchi, A., et al. Blockade of RAGE/amphoterin suppresses tumor growth and metastases. Nature 405, 354-360 (2000).
- 30 9. Rauvala, H., et al. The adhesive and neurite-promoting molecule p30: analysis of the amino terminal sequence and production of antipeptide antibodies that detect

p30 at the surface of neuroblastoma cells and of brain neurons. J Cell Biol 107, 2293-2305 (1987).

5 10. Hori, O., et al. RAGE is a cellular binding site for amphotericin: mediation of neurite outgrowth and co-expression of RAGE and amphotericin in the developing nervous system. J Biol Chem 270, 25752-25761 (1995).

10 11. Schafer, B. & Heizmann, C. The S100 family of EF-hand calcium-binding proteins: functions and pathology. TIBS 21, 134-140 (1996).

15

20

25

30

What is claimed is:

1. A method for treating a subject either during or soon after a seizure, in order to reduce the extent of neuronal damage in the subject resulting from the seizure comprising administering to the subject, either during or soon after the seizure, a therapeutically effective amount of an inhibitor of receptor for advanced glycation endproducts (RAGE), so as to thereby reduce the extent of neuronal damage in the subject.
2. The method of claim 1, wherein the subject is a human.
3. The method of claim 1, wherein the neuronal damage comprises cell death in the hippocampus and/or cerebral cortex.
4. The method of claim 1, wherein the neuronal damage comprises cell dysfunction in the hippocampus and/or cerebral cortex.
5. The method of claim 1, wherein the inhibitor is an antibody which, when contacted with RAGE, specifically inhibits binding between RAGE and a ligand thereof.
6. The method of claim 1, wherein the inhibitor is an anti-sense molecule which specifically inhibits the expression of RAGE in a cell.

7. The method of claim 1, wherein the inhibitor is an RNAi molecule which specifically inhibits the expression of RAGE in a cell.

5

8. The method of claim 1, wherein the inhibitor is a catalytic nucleic acid which specifically inhibits the expression of RAGE in a cell.

10

9. The method of claim 1, wherein the inhibitor is administered during the seizure.

10. The method of claim 1, wherein the inhibitor is administered within three days of the seizure.

15

11. The method of claim 1, wherein the inhibitor is administered within one day of the seizure.

12. The method of claim 1, wherein the inhibitor is administered within six hours of the seizure.

20

13. The method of claim 1, wherein the inhibitor is administered within one hour of the seizure.

14. The method of claim 1, wherein the inhibitor is administered within 20 minutes of the seizure.

25

15. A method for inhibiting neuronal damage which would otherwise result from a seizure in a subject predisposed to having a seizure, comprising administering to the subject a prophylactically effective amount of an inhibitor

30

of receptor for advanced glycation endproducts (RAGE), so as to inhibit neuronal damage which would otherwise result from a seizure in the event the subject were to suffer a seizure.

5

16. The method of claim 15, wherein the subject is human.

10

17. The method of claim 15, wherein the neuronal damage comprises cell death in the hippocampus and/or cerebral cortex.

15

18. The method of claim 15, wherein the neuronal damage comprises cell dysfunction in the hippocampus and/or cerebral cortex.

20

19. The method of claim 15, wherein the inhibitor is an antibody which, when contacted with RAGE, specifically inhibits binding between RAGE and a ligand thereof.

25

20. The method of claim 15, wherein the inhibitor is an anti-sense molecule which specifically inhibits the expression of RAGE in a cell.

30

21. The method of claim 15, wherein the inhibitor is an RNAi molecule which specifically inhibits the expression of RAGE in a cell.

22. The method of claim 15, wherein the inhibitor is a catalytic nucleic acid which specifically inhibits the expression of RAGE in a cell.

23. An article of manufacture comprising (a) a packaging material having therein an inhibitor of receptor for advanced glycation endproducts (RAGE) and (b) instructions for using the inhibitor to treat a subject during or soon after a seizure, in order to reduce the extent of neuronal damage in the subject resulting from the seizure.

24. An article of manufacture comprising (a) a packaging material having therein an inhibitor of receptor for advanced glycation endproducts (RAGE) and (b) instructions for using the inhibitor to inhibit neuronal damage which would otherwise result from a seizure in a subject predisposed to having a seizure.

METHODS FOR REDUCING SEIZURE-INDUCED NEURONAL DAMAGEAbstract of the Disclosure

5 This invention provides a method for treating a subject
either during or soon after a seizure, in order to reduce
the extent of neuronal damage in the subject resulting from
the seizure comprising administering to the subject, either
during or soon after the seizure, a therapeutically
10 effective amount of an inhibitor of receptor for advanced
glycation endproducts (RAGE), so as to thereby reduce the
extent of neuronal damage in the subject. This invention
further provides a method for inhibiting neuronal damage
which would otherwise result from a seizure in a subject
15 predisposed to having a seizure, comprising administering
to the subject a prophylactically effective amount of an
inhibitor of receptor for advanced glycation endproducts
(RAGE), so as to inhibit neuronal damage which would
otherwise result from a seizure in the event the subject
20 were to suffer a seizure. This invention further provides
related articles of manufacture.



103103

PTO/SB/18

Approved for use through 07/31/2006. OMB 0651-0046
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).

Express Mail Label No. EV325709125US

730025 U.S. PTO
60/516323

103103

INVENTOR(S)					
Given Name (first and middle (if any))		Family Name or Surname		Residence (City and either State or Foreign Country)	
Shi Du		Yan		New York, New York	
Additional inventors are being named on the <u>1</u> separately numbered sheets attached hereto					
TITLE OF THE INVENTION (500 characters max)					
METHODS FOR REDUCING SEIZURE-INDUCED NEURONAL DAMAGE					
Direct all correspondence to: CORRESPONDENCE ADDRESS					
<input type="checkbox"/> Customer Number: 					
OR					
<input checked="" type="checkbox"/> Firm or Individual Name		John P. White			
Address		COOPER & DUNHAM LLP			
Address		1185 Avenue of the Americas			
City		New York		State	NY
Country		USA		Zip	10036
		Telephone	212-473-0400	Fax	212-391-0525
ENCLOSED APPLICATION PARTS (check all that apply)					
<input checked="" type="checkbox"/> Specification Number of Pages <u>16</u>		<input type="checkbox"/> CD(s), Number _____			
<input type="checkbox"/> Drawing(s) Number of Sheets _____		<input type="checkbox"/> Other (specify) _____			
<input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76					
METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT					
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.		FILING FEE Amount (\$)			
<input checked="" type="checkbox"/> A check or money order is enclosed to cover the filing fees.		<div style="border: 1px solid black; padding: 10px; text-align: center;">\$160.00</div>			
<input checked="" type="checkbox"/> The Director is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number: <u>03-3125</u>					
<input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.					
The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.					
<input checked="" type="checkbox"/> No.					
<input type="checkbox"/> Yes, the name of the U.S. Government agency and the Government contract number are: _____					

[Page 1 of 2]

Respectfully submitted,

Date October 31, 2003

SIGNATURE _____

REGISTRATION NO. 37,399TYPED or PRINTED NAME Alan J. Morrison

(if appropriate)

Docket Number: 68548-PROTELEPHONE 212-278-0400**USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT**

This collection of information is required by 37 CFR 1.51. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Provisional Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

103103

PTO/SB/16 (08-03)

Approved for use through 07/31/2006. OMB 0851-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Docket Number 68548-PRO

INVENTOR(S)/APPLICANT(S)		
Given Name (first and middle (if any))	Family or Surname	Residence (City and either State or Foreign Country)
David	Stem	Great Neck, New York
Guy	McKhann	New York, New York

[Page 2 of 2]

Number 2 of 2

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.



103103

Docket No. 68548-PRO/JPW/AJM/JCS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Shi Du Yan, et al.
Serial No.: Not Yet Known
Filed: Herewith
For: METHODS FOR REDUCING SEIZURE-INDUCED NEURONAL
DAMAGE

1185 Avenue of the Americas
New York, New York 10036

Mail Stop Provisional Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SIR:

EXPRESS MAIL CERTIFICATE OF MAILING
FOR ABOVE-IDENTIFIED APPLICATION

"Express Mail" mailing label number: EV 325 709 125 US

Date of Deposit: October 31, 2003

I hereby certify that this paper or fee is being deposited to the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. \$1.10 on the date indicated above and is addressed to Mail Stop Provisional Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Printed Name: T. 1500A

Respectfully submitted,

Alan J. Morrison
Registration No. 37,399
Attorney for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
Tel. No. (212) 278-0400